


REMARKS/ARGUMENTS

Claims 77 and 87, which were introduced in the “Reply to Office Action” dated October 4, 2010, have been amended to further clarify the claimed subject matter. In particular, the phrase “wherein the ECAT2 gene comprises the nucleotide sequence of SEQ ID NO: 5 or 7” has been replaced with the phrase “wherein the ECAT gene encodes the amino acid sequence of SEQ ID NO: 6 or 8.” The amendments to claims 77 and 87 are supported by the specification at, for example, Table 1. Therefore, no new matter has been added by way of the amendments to the claims.

Applicants respectfully submit that the patent application is in condition for allowance. If, in the opinion of the Examiner, a telephone conference would expedite the prosecution of the subject application, the Examiner is invited to call the undersigned attorney.

Respectfully submitted,


John Kilyk, Jr., Reg. No. 30,763
LEYDIG, VOIT & MAIER, LTD.
Two Prudential Plaza, Suite 4900
180 North Stetson Avenue
Chicago, Illinois 60601-6731
(312) 616-5600 (telephone)
(312) 616-5700 (facsimile)

Date: October 6, 2010